Sakae Asanuma is Director & 10% Owner at Werewolf Therapeutics, Inc. (HOWL). They have made 1 open-market trade across 1 company since 2020, most recently 2021-05-04.
CIK 0001857822
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $5.0M since 2020, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| HOWL | 1,318,311 | $1.3M |
Shares reported on the most recent Form 4, priced at the 2021-05-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| HOWL | BUY | 2021-05-04 | 2021-05-04 | $16.00 | $5.0M | -29.5% | -21.6% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.